The website Blisstree published “Three Years Later, The FDA Revisits Concern Over The Safety Of Yaz” on December 5th. The article discusses the marketing methodology of Bayer and the forthcoming review of Yaz by the FDA:
Yaz gained popularity, mostly because it was aggressively marketed, boasting that it could not only keep you from getting pregnant, but also that it could also clear up your skin, and came with fewer side-effects than other drugs. Unfortunately, Yaz and similar pills, which contain an ingredient called drospirenone, quickly became something
of a birth control pariah when young, healthy women began developing blood clots. Researchers immediately began studying the safety of the pill...a process which takes a painfully long time.
The results of that research have shown that Yaz and Yasmin are indeed associated with a higher risk of blood clots and associated complications than competing birth control pills. The overall conclusion of the article is that it’s a good thing that the FDA is reexamining the safety of Yaz, even if that reexamination is long overdue. I couldn’t agree more.
Comments